This paper reports the clinical characteristics, diagnosis, and treatment of myself after being infected with Covid-19. After comprehensive treatment including nasal cannula oxygen therapy, antiviral and anti-infection therapies, liquid volume management, glucocorticoids, analgesia and sedation, blood tests control, anticoagulation, and thrombus prevention, and electrolyte balance maintenance, after 24 days finally my health situation was good. The purpose of this case report is to provide a reference for the clinical diagnosis and treatment of myself, in-home condition in this critical situation.
Siddiqi, HK, and Mehra, MR. 2020. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 39: 405–407
Richard B Aguilar, Patrick Hardigan, Apr 2020 Current Understanding of COVID-19 clinical Course and Investigational Treatments (Fig.1 reference 1-12)
Zhou F, et al. Clinical Course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395, 1054-1062.
Yang X, et al. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine.
Hsueh PR, et al. Chronological evolution of IgM, IgA, IgG, and neutralization antibodies after infection with SARS-associated coronavirus. Clin Microbial Infect. 2004 Dec;10(12); 1062-6
Siddiqu HK, J Heart Lung Transplant. March 25th, 2020 DOI: 10.1016/j.healun.2020.03.012 COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal
Ware Lb, Matthay MA. The acute respiratory distress syndrome. N Engl J. Med. 2000;342; 1334-1349.
E de Wit, Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Science Mar 2020, 117 6771-6776; DOI; 10,1073/pnas.1922083117
Yao X, Ye, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARRS-CoV-2), Clin Infect Dis, [published online March 9, 2020], DOI: 10.1093/cid/ciaa237
Gauntret P, et al. Int J Antimicrob Agents. 2020 Mar 20: 10594, DOI 10.1016/j.inantimicrag.2020.105949 Hydroxychloroquine and azithromycin as a treatment of COVID-19 open-label non-randomized trial
Shen C, et al. treatment of 5 Critically III Patients With COVID-19 With Convalescent Plasma. JAMA. Published online March 27, 2020, doi:10.1001/jama.2020.4783
Sadhi M, Ethmian M. Therapeutic potential for tetracyclines in the treatments of COVID-19. (April8, 2020). Retrieved April 11, 2020. Pharmacotherapy. 2020 Apr 8, DOI: 10.1002/phar,2395.
Chen R, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 2006; 129:1441-52.
Chen R, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 2006; 129:1441-53.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad, spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–63.
Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.
Grasselli G, Zangrillo A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region. Italy JAMA. 2020; 323 (16):1574–81.
Maryam Edalatifard, Maryam Akhtari. J 2020 European Respiratory Journal.
Intravenous methylprednisolone pulse as a treatment for hospitalized severe COVID-19 patients: results from a randomized controlled clinical trial. https://doi.org/10.1183/13993003.02808-2020
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.